ArticleBiology2026
In Silico Evaluation via Virtual Screening, ADMET Profiling and Molecular Dynamics Simulations: Synthesis and Biological Activity Analysis of a Novel Antitumor PI3K Inhibitor.
Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PI3K plays a crucial role in cancer progression, and the development of PI3K inhibitors has always been a hot research direction in oncology. Through virtual screening and docking, potential lead compounds were identified. ADMET prediction revealed that KTC101 possesses superior pharmacokinetic profile. Molecular dynamics simulations indicated that compound KTC101 could stably bind to PI3Kδ, with a binding free energy of -374.627 kJ/mol. Analysis of the metabolism of KTC101 revealed that this compound could undergo diverse phase I metabolic reactions catalyzed by hepatic CYP450 enzymes to form highly polar metabolites, indicating its strong metabolic potential and easy metabolic clearance in vivo. Then it was synthesized and evaluated for kinase inhibitory activity and antiproliferative effects in HNSCC cell lines. KTC101 was first reported as a PI3K inhibitor, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.